Related Experiment Video
Updated: Jan 20, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
FGF23, Hypophosphatemia, and Emerging Treatments
Erik A Imel1, Andrew Biggin2,3, Aaron Schindeler2,4
1Division of Endocrinology Indiana University School of Medicine, Indianapolis, IN USA.
Fibroblast growth factor 23 (FGF23) regulates phosphate balance. Burosumab, an FGF23 antibody, shows promise for treating X-linked hypophosphatemia (XLH) and potentially other FGF23-related disorders.
Area of Science:
- Endocrinology
- Mineral Metabolism
- Genetics
Background:
- Fibroblast growth factor 23 (FGF23) is a key hormone regulating phosphate homeostasis and vitamin D metabolism.
- X-linked hypophosphatemia (XLH) and other FGF23-mediated hypophosphatemias result from excessive FGF23 activity, leading to phosphaturia and abnormal calcitriol levels.
- Traditional treatments for hypophosphatemia include phosphate and active vitamin D analogs, but these have limitations.
Purpose of the Study:
- To review the clinical trial progression and recent availability of burosumab, a neutralizing antibody for FGF23.
- To discuss the potential of burosumab in treating X-linked hypophosphatemia (XLH).
- To explore the potential application of burosumab in other conditions associated with FGF23 overactivity.
Main Methods:
- Review of clinical trial data for burosumab in XLH treatment.
- Analysis of burosumab's mechanism of action as an FGF23 inhibitor.
- Discussion of current therapeutic strategies and emerging treatments for FGF23-mediated hypophosphatemia.
Main Results:
- Burosumab has demonstrated efficacy in clinical trials for XLH.
- Burosumab is now available for clinical use in treating XLH.
- Further research is needed to establish burosumab's efficacy in other FGF23-related disorders.
Conclusions:
- Burosumab represents a significant advancement in treating FGF23-mediated hypophosphatemia, particularly XLH.
- The availability of burosumab offers a targeted therapy for conditions driven by FGF23 excess.
- Future studies are warranted to investigate burosumab's broader therapeutic potential in endocrinology and mineral metabolism.
Related Concept Videos
Emerging Adulthood
Guidelines in Case of a Laboratory Emergency
The most common laboratory emergencies include chemical spills, fire or explosion, electric shock, and personnel injuries. Most laboratory accidents occur due to poor planning or lack of attention. Therefore, it's always better to prevent accidents (being proactive) than having to take any actions during an emergency (being reactive). For example, always wear proper personal protective equipment (PPE) in the...
06:59A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Introduction Cardiac Emergencies
Emergency Eyewash and Shower Stations
The Occupational Safety and Health Administration (OSHA) mandates that an emergency eyewash and shower station be easily accessible in all workplaces in which a person could be exposed to injurious and/or corrosive substances. Emergency eyewash and shower stations should be used in the case of a laboratory or workplace accident that involves the spilling of a harmful, possibly corrosive chemical onto the body or the splashing...
Applications of GIS: Disaster Management and Emergency Response